Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fulcrum Therapeutics (FULC) Non-cash Items: 2019-2024

Historic Non-cash Items for Fulcrum Therapeutics (FULC) over the last 6 years, with Dec 2024 value amounting to $4.3 million.

  • Fulcrum Therapeutics' Non-cash Items rose 3239.76% to $43.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $43.3 million, marking a year-over-year increase of 3239.76%. This contributed to the annual value of $4.3 million for FY2024, which is 34.87% up from last year.
  • Latest data reveals that Fulcrum Therapeutics reported Non-cash Items of $4.3 million as of FY2024, which was up 34.87% from $3.2 million recorded in FY2023.
  • Fulcrum Therapeutics' Non-cash Items' 5-year high stood at $5.8 million during FY2020, with a 5-year trough of $1.5 million in FY2021.
  • Over the past 3 years, Fulcrum Therapeutics' median Non-cash Items value was $3.2 million (recorded in 2023), while the average stood at $3.2 million.
  • In the last 5 years, Fulcrum Therapeutics' Non-cash Items soared by 1,758.08% in 2020 and then tumbled by 74.40% in 2021.
  • Over the past 5 years, Fulcrum Therapeutics' Non-cash Items (Yearly) stood at $5.8 million in 2020, then tumbled by 74.40% to $1.5 million in 2021, then skyrocketed by 43.30% to $2.1 million in 2022, then surged by 52.41% to $3.2 million in 2023, then spiked by 34.87% to $4.3 million in 2024.